GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Combined entity is better positioned to compete in increasingly competitive generics industry
The facility was inspected from May 7 to May 17, 2024
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
_256_384.jpg)
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
